Metagenomi Therapeutics, Inc. balance sheet MGX

Annual Quarterly

As of Jun 30, 2026, Metagenomi Therapeutics, Inc. had total assets of $173.7 million and total liabilities of $61.1 million. Total assets were down 36.2% from a year earlier. Stockholders' equity was $112.6 million. It held $122.8 million in cash and investments against $37.7 million of total debt, net cash of $85.1 million. The current ratio, current assets divided by current liabilities, was 4.50.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the same quarter a year earlier.

Q2 FY2026
Jun 30, 2026
Q1 FY2026
Mar 31, 2026
Q4 FY2025
Dec 31, 2025
Q3 FY2025
Sep 30, 2025
Q2 FY2025
Jun 30, 2025
Q1 FY2025
Mar 31, 2025
Q4 FY2024
Dec 31, 2024
Q3 FY2024
Sep 30, 2024
Assets
Cash
39
+45.4%
25
-13.3%
42
+52.3%
33
+30.5%
27
-56.1%
29
-71.5%
27
25
Short-term investments
82
-54.2%
115
-41.6%
119
-46.1%
151
-39.3%
178
-25.4%
197
-12.5%
221
249
Long-term investments
2
+0.0%
2
-37.5%
2
-37.5%
2
-79.6%
2
-79.8%
3
-67.7%
3
11
Cash and investments
123
-40.7%
142
-38.0%
163
-35.3%
186
-34.7%
207
-33.3%
229
-32.1%
252
285
Receivables
0
-100.0%
0
-100.0%
—
—
1
1
—
—
Total current assets
124
-41.2%
145
-38.0%
166
-35.8%
190
-32.8%
212
-31.2%
233
-30.5%
258
282
Property and equipment, net
10
-34.5%
11
-32.4%
12
-30.7%
14
-29.5%
15
-27.0%
17
-21.2%
18
20
Total assets
174
-36.2%
197
-33.9%
221
-31.9%
248
-30.8%
272
-29.4%
298
-28.3%
325
358
Liabilities and equity
Accounts payable
3
-10.0%
2
-10.2%
1
+179.4%
1
-60.8%
3
-16.3%
3
-61.0%
1
3
Total current liabilities
28
-16.9%
22
-43.6%
23
-38.5%
30
-35.3%
33
-37.0%
40
-43.6%
37
46
Total liabilities
61
-20.0%
59
-30.6%
63
-30.3%
69
-32.3%
76
-34.4%
85
-39.0%
90
103
Stockholders' equity
113
-42.5%
138
-35.2%
159
-32.5%
178
-30.2%
196
-27.3%
213
-22.8%
235
256
Debt
Lease liabilities
38
-12.3%
39
-11.8%
41
-11.2%
42
-9.6%
43
-10.3%
44
-7.5%
46
46
Total debt
38
-12.3%
39
-11.8%
41
-11.2%
42
-9.6%
43
-10.3%
44
-7.5%
46
46
Net cash
85
-48.2%
103
-44.2%
122
-40.6%
145
-39.5%
164
-37.5%
185
-36.2%
206
239
Ratios
Current ratio
4.50x
6.43x
7.22x
6.42x
6.36x
5.85x
6.91x
6.18x
Debt to equity
0.34x
0.28x
0.26x
0.23x
0.22x
0.21x
0.19x
0.18x
Return on equity
-83.03%
-62.33%
-55.40%
-49.73%
-44.49%
-36.65%
-33.24%
—
Return on assets
-53.81%
-43.61%
-39.74%
-35.79%
-32.00%
-26.17%
-24.05%
—
Book value per share
2.98
3.66
4.22
4.75
5.22
5.69
6.28
6.83
How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
MGX (Nasdaq)
Fiscal year ends
December 31
Headquarters
Emeryville, CA
SEC filer status
, Emerging growth company
SEC CIK
1785279
Former names
Metagenomi, Inc. (until Jan 12, 2026); Metagenomi Technologies, LLC (until Jan 18, 2024)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.